The ProVIDe study: the impact of protein intravenous nutrition on development in extremely low birthweight babies

A multicentre, double-blind, randomised, controlled trial enrolling 430 extremely low birthweight babies (birthweight <1000 g) who have an umbilical arterial line. Participants are randomized to receive either the amino acid solution or placebo (saline).

The ProVIDe study assesses the impact of administering an additional 1 to 2 g/kg/d of protein (TrophAmine®) through an umbilical arterial catheter for 5 days post-birth in extremely low birthweight babies.

The trial aims to determine if increased protein intake improves survival free from neurodevelopmental disability at 2 years’ corrected age, as well as body composition and growth.